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Abstract
CDKN2A encodes proteins such as p16 (INK4a), which negatively regulate the cell-cycle. Molecular genetic studies have revealed 
that deletions in CDKN2A occur frequently in cancer. Although p16 (INK4a) may be involved in tumor progression, the clinical 
impact and prognostic implications in head and neck squamous cell carcinoma (HNSCC) are controversial. The objective of this 
study was to evaluate the frequency of the immunohistochemical expression of p16 (INK4a) in 40 oropharynx and 35 larynx from 
HNSCC patients treated in a single institution and followed-up at least for 10 years in order to explore potential associations with 
clinicopathological outcomes and prognostic implications. Forty cases (53.3%) were positive for p16 (INK4a) and this expression 
was more intense in non-smoking patients (P = 0.050), whose tumors showed negative vascular embolization (P = 0.018), negative 
lymphatic permeation (P = 0.002), and clear surgical margins (P = 0.050). Importantly, on the basis of negative p16 (INK4a) expres-
sion, it was possible to predict a probability of lower survival (P = 0.055) as well as tumors presenting lymph node metastasis (P = 
0.050) and capsular rupture (P = 0.0010). Furthermore, increased risk of recurrence was observed in tumors presenting capsular 
rupture (P = 0.0083). Taken together, the alteration in p16 (INK4a) appears to be a common event in patients with oropharynx and 
larynx squamous cell carcinoma and the negative expression of this protein correlated with poor prognosis.
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CDKN2A (also known as ARF, MLM, p14, p16, p19, 
CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4a, 
p14ARF, p19Arf, p16INK4, p16INK4a, and CDKN2A), a 
tumor suppressor gene mapped on chromosome 9p21, 
encodes proteins, whose main function is the negative 
cell-cycle regulation (1). The p16 (INK4a) protein is a cyclin-
dependent kinase inhibitor (CDKI) that reduces the rate of 
the cell-cycle by inactivation of specific cyclin-protein kinase 
complexes such as cyclin-dependent kinases (CDK) type 
D1 (CCND1), CDK4, and CDK6 (2-4). The CDKs phos-
phorylate the retinoblastoma protein (pRb), which results 
in a conformational change leading to the interruption of 
the cell-cycle progression (5,6). The inactivation of either 
p16 (INK4a) or pRb function allows the cell to enter in the 
S phase after only a pause at the G1 checkpoint (6).
The loss of p16 (INK4a) through homologous deletion, 
point mutation or methylation-induced promoter silencing 
has also been widely observed in cancer cell lines and some 
malignant tumors, such as acute lymphoblastic leukemia 
(3,4,7), melanomas (8), pancreatic cancer (9), esophagus 
(10), lung (11), bladder (1), cervical (12), and head and neck 
squamous cell carcinomas (HNSCC) (6,13). Additionally, the 
absence of p16 (INK4a) is an early and often critical event 
in tumor progression, once that deletion in at least one copy 
is quite high in premalignant lesions giving selective advan-
tage to neoplastic cells (14). Recent studies have shown 
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that knockout mice of p16 (INK4a) have more spontaneous 
tumors and increased cancer susceptibility when exposed 
to carcinogen agents than wild-type mice (2).
Despite the tremendous progress in surgical techniques, 
radiotherapy, and chemotherapy, the prognosis for patients 
with HNSCC has been only slightly improved during the 
past three decades (15). Chemotherapy has produced 
unsatisfactory results in head and neck tumors and novel 
approaches, including treatment tailoring by pharmaco-
genetic analysis and new molecular-targeted drugs, are 
required. Gene therapy is emerging as potentially effica-
cious techniques for many tumors. However, the scarcity 
of effective therapies may reflect the lack of knowledge 
about the influence of tumor-related molecular abnormali-
ties on responsiveness to drugs and how it can impact on 
patient survival. Although some studies have examined the 
association between molecular markers in HNSCC, few 
have evaluated their effects on survival. Among those that 
have attempted to examine these effects, few examined 
the molecular markers adjusting for effects of clinical stage, 
lifestyle habits, and pathological characteristics. Thus, the 
prognostic significance remains to be addressed in patients 
with oropharynx and larynx squamous cell carcinoma. In 
this report, we showed the clinicopathological impact and 
prognostic implications of negative p16 (INK4a) expression 
in HNSCC patients followed-up for at least 10 years.
Material and Methods
Study population
A retrospective study was performed by analyzing 40 
oropharynx and 35 larynx specimens from primary HNSCC 
patients (all histological diagnosis were confirmed) diag-
nosed and treated at the Department of Head and Neck Sur-
gery and Otorhinolaryngology, A.C. Camargo Hospital, São 
Paulo, Brazil. The eligibility criteria included previously un-
treated patients with diagnosis of squamous cell carcinoma 
submitted to treatment only in this institution. Demographic 
(age, gender, and race), lifestyle (smoking habit and alcohol 
consumption), clinical (macroscopy, tumor site, and clinical 
stage), and pathological factors (histological grade, vascular 
embolization, perineural infiltration, lymphatic permeation, 
capsular rupture, and surgical margins) were analyzed. The 
tumors were staged according to the 2002 version of the 
International Union Against Cancer (TNM) classification 
and grouped as early (T1+T2) or advanced clinical stage 
(T3+T4). All cases were followed-up after treatment, with 
disease recurrence being confirmed microscopically. The 
histological grade was determined on the basis of the 
classification proposed by the World Health Organization 
(16). Vascular embolization and lymphatic permeation 
were classified according to the presence or absence of 
neoplastic cells, located both in the wall and lumen of the 
blood or lymphatic vessels, respectively; perineural infiltra-
tion was considered to be present when the tissue adjacent 
to the peri- and/or intra-tumoral nerves was involved by 
the neoplastic cells; surgical margins were considered to 
be involved when invasive and/or in situ carcinoma was 
observed in the margins of the surgical specimens. This 
study was carried out with approval of the Human Research 
Ethics Committee of Hospital A.C. Camargo.
Tissue microarray (TMA) and immunohistochemistry
To construct the TMA, core biopsies were taken from 
previously defined areas, with a Tissue Microarray ap-
paratus (Beecher Instruments®, USA). Tissue cores with 
1.0 mm were punched from each specimen and arrayed in 
duplicate on a recipient paraffin block. Cores were spaced 
0.2 mm apart. After cutting (3 µm) on the recipient block 
and transferring with an adhesive tape to coated slides for 
subsequent UV cross-linkage (Instrumedics Inc.®, USA), 
the slides were dipped in paraffin to prevent oxidation, and 
maintained in a -20°C freezer.
For immunostaining, the sections were deparaffinized 
and rehydrated in graded ethanol solutions, treated with 
peroxide to quench endogenous peroxidase (0.3% H2O2 for 
15 min) and blocked for avidin/biotin (DAKO Biotin Block-
ing System®, Dako Cytomation, Denmark) and for protein 
(DAKO® Protein Block Serum-Free, Dako Cytomation). 
Antigen recovery was performed by wet heating in a pres-
sure cooker. Slides were incubated with anti-p16 (INK4a; 
Santa Cruz, USA, 1:200). The immunohistochemical reac-
tion was carried out in duplicate at different TMA levels, 
representing 4-fold redundancy for each case. Positive 
and negative controls were included in all reactions. p16 
(INK4a) was assessed by two kinds of negative controls: 
1) omitting the primary antibody and incubating slides with 
phosphate-buffered saline; 2) replacing the primary anti-
body with normal mouse serum. After scanning each tumor 
specimen in a low-power field to choose the most stained 
area, at least five fields were evaluated under high power. 
The presence of a clearly visible dark brown precipitation 
was considered to be an immunoreaction. The cells were 
considered to be positive if they showed intense diffuse 
staining on the slides. Focal staining was scored as p16 
(INK4a) negative. Evaluation of p16 (INK4a) included the 
nuclear proportion of reactive cells within the tumors and 
the staining intensity. The two pathologists who scored the 
immunostaining to determine the percentage and color 
intensities of stained cells were blind to the outcome and 
clinical aspects of each tumor specimen. Each core was 
scanned in low-power field to choose the most stained area 
predominant in at least 10% of tumor cells (17).
Statistical analysis
For frequency analysis of contingency tables, statisti-
cal analyses of associations between variables were per-
formed by the chi-square test or the Fisher exact test (with 
significance set at P < 0.05). The overall survival (OS) was 
defined as the interval between the beginning of treatment 
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and the date of death or the last information for censored 
observations. The disease-free interval (DFI) was measured 
from the date of treatment to the date when recurrence was 
diagnosed. Overall survival and disease-free survival prob-
abilities were estimated by the Kaplan-Meier method, and 
the log-rank test was applied to assess the significance of 
differences among actuarial survival curves. For statistical 
analysis, the samples were categorized into two groups: 
negative versus positive reaction. All analyses were per-
formed using the statistical software package STATA (STATA 
Corporation, USA). 
Results
The study population consisted of 75 patients, 71 
(94.7%) males and 4 (5.3%) females, with a mean age of 58 
years (range 21-76 years). A history of alcohol consumption 
was observed in 62 (87.3%) patients and tobacco smoking 
in 71 (94.7%). With regard to the ethnic group, 67 (89.3%) 
were Caucasians and 8 (10.7%) non-Caucasians. The time 
of complaint was defined as the time between the date of 
recognition of the first sign or symptom of the disease by 
the patient and the date of first visit to a professional who 
was qualified to refer the patient for definitive diagnosis and 
treatment. The mean time of the complaint was 5 months 
(range 1-72 months). The oropharynx was the most frequent 
site (45 cases, 53.3%), followed by the larynx (30 cases, 
46.7%). A total of 22 cases (33.3%) were in an early clinical 
stage (T1+T2) and 44 (66.7%) in an advanced clinical stage 
(T3+T4). Twenty-seven patients had metastatic cervical 
lymph nodes (40.9%). Vascular embolization was detected 
in 57 of the 75 eligible cases (79.2%), lymphatic permeation 
in 46 (63.9%), perineural infiltration in 32 (44.4%), and 
involved margins in 6 (8.6%). Twenty-six cases (34.7%) 
were histologically well differentiated (grade I), 42 cases 
(56%) moderately differentiated or grade II and 6 cases 
(9.3%) poorly differentiated or grade III. 
The immunohistochemical results are summarized in 
Table 1. p16 (INK4a) positivity was nuclear and intracyto-
plasmic (Figure 1A). Forty cases (53.3%) were positive for 
p16 (INK4a; Figure 1A) and this positivity was more intense 
in non-smoker patients (P = 0.050), presenting negative 
vascular embolization (P = 0.018), negative lymphatic 
permeation (P = 0.002), and clear surgical margins (P = 
0.050) (Table 1). Thirty-five cases were negative (46.7%; 
Figure 1B).
Twenty-nine (39.7%) patients had tumor recurrence 
during the study within a mean time of 23.2 months (range 
1-87.7 months). At the end of the follow-up period, 36 (48%) 
patients were alive and 39 (52%) had died (Table 1). Thirty-
six (48%) patients died because of the HNSCC and 3 (4%) 
of other causes during follow-up. OS time ranged from 1 
to 126.13 months (mean: 55.5 months). The 5-year rates 
for OS and DFI were 56 and 64%, respectively (Figure 2A 
and B). Importantly, our data show that p16 (INK4a) im-
Table 1. Correlation between p16 (INK4a) protein expression 
and clinicopathological variables in head and neck squamous 
cell carcinomas.
Characteristics p16 (INK4a) [N (%)]
Negative Positive
Gender
Male 33 (46.5) 38 (53.5)
Female 2 (50) 2 (50)
Race
Caucasian 32 (47.8) 35 (52.2)
Non-Caucasian 3 (37.5) 5 (62.5)
Smoking habit
No 0*   4 (100)
Yes 35 (49.3) 36 (50.7)
Alcohol consumption
No 6 (46.2) 7 (53.8)
Yes 29 (46.8) 33 (53.2)
Tumor site
Pharynx 30 (47.6) 33 (52.4)
Larynx 5 (41.7) 7 (58.3)
T stage
T1+T2 8 (36.4) 14 (63.6)
T3+T4 23 (52.3) 21 (47.7)
Lymph nodes
N0 19 (48.7) 20 (51.3)
N+ 12 (44.4) 15 (55.6)
Histological grade
I 14 (53.8) 12 (46.2)
II 19 (45.2) 23 (54.8)
III 2 (28.6) 5 (71.4)
Vascular embolization
No 3 (20)* 12 (80)
Yes 31 (54.4) 26 (45.6)
Lymphatic permeation
No 6 (23.1)* 20 (76.9)
Yes 28 (60.9) 18 (39.1)
Perineural infiltration
No 21 (52.5) 19 (47.5)
Yes 13 (40.6) 19 (59.4)
Capsular rupture
No 23 (52.3) 21 (47.7)
Yes 12 (40) 18 (60)
Surgical margins
Negative 27 (42.2)* 37 (57.8)
Positive 5 (83.3) 1 (16.7)
Status
Alive 14 (38.9) 22 (61.1)
Dead 21 (53.8) 18 (46.2)
Data are reported as number with percent (considering cases 
with complete information) in parentheses. *P < 0.05 (chi-square 
or Fisher exact tests).
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munolabeling was able to predict the overall 
survival probability (log-rank test, P = 0.055), 
since patients whose tumors showed positive 
intracytoplasmic p16 (INK4a) expression had 
a higher overall survival than patients with 
negative reactions (Figure 2C). There was 
a significantly lower survival probability for 
patients with lymph node metastasis (log-rank 
test, P = 0.050) (Figure 2D) and the presence 
of capsular rupture (log-rank test, P = 0.0010) 
(data not shown). According to the primary 
site, patients with tumors in the oropharynx 
(56.7%) had shorter 5-year overall survival 
rates than patients with lesions in the larynx 
(47.4%), although the OS curves did not differ 
significantly (P = 0.495). DFI ranged from 1 to 
87 months (mean: 23.2 months). Association 
with a higher risk of recurrence was observed 
in tumors presenting capsular rupture (log-
rank test, P = 0.0083). In the present study, 
no association occurred between p16 (INK4a) 
expression and disease-free survival (log-rank 
test, P = 0.0788) (data not shown).
Discussion
Since its discovery as a CDKI in 1993, the 
tumor suppressor p16 (INK4a) has gained 
widespread importance in cancer research 
(1,4,7-13,18,19). The frequent mutations and 
deletions of CDKN2A in human cancer cell 
lines first suggested an important role for p16 
(INK4a) in carcinogenesis rivaled in frequency 
only by the p53 tumor suppressor gene (20). 
The present study provides further insight 
into the real clinicopathological impact and 
prognostic implications of p16 (INK4a) im-
munohistochemical expression in a particular 
set of 75 HNSCC patients followed up on a 
long-term basis for at least 10 years.
In human neoplasms, CDKN2A is silenced 
in at least three ways: homozygous deletion, 
methylation of the promoter, and point muta-
tion. The first two mechanisms are responsible 
for the majority of inactivation events in most 
primary tumors (20). The mechanism of action of the CDKI 
p16 (INK4a) blocks the transcription of important cell-cycle 
regulatory proteins among them, the enzymes phosphorylat-
ing pRb and it results in cell-cycle arrest (5,6). pRb inacti-
vation is usually reciprocal with p16 (INK4a) expression in 
several tumors (6,21,22). Even though the molecular basis 
for overexpression of p16 (INK4a) in HNSCC is unclear, 
some studies have evaluated the relationship between p16 
(INK4a) and human papillomavirus (HPV), suggesting that 
the activation of p16 (INK4a) in cell-cycle regulatory cascade 
may be linked with HPV status (3,23-26). Recently, it has 
become increasingly clear that HPVs replicate by interfer-
ing with normal cell cycle control mechanisms. Evidence 
suggests that malignant transformation is intimately related 
to these processes, and that the oncogenic potential of 
papillomaviruses probably lies in their ability to alter cell 
cycle checkpoints, thereby leading to the accumulation 
and transmission of genetic abnormalities (27). Studies 
have shown that the E6 and E7 oncoproteins of high-risk 
HPVs, particularly HPV 16 and HPV 18, respectively bind 
Figure 1. Representative immunohistochemical reactions for p16 (INK4a) in 
75 head and neck squamous cell carcinoma (HNSCC) samples. Positive p16 
(INK4a) reaction was found in 53.3% of the HNSCC (A), whereas morphologi-
cally normal areas (spotted in the tumor microarray as control) and 46.7% of 
the tumors showed negative expression (B). Bar = 100 µm for both panels.
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to the p53 and pRb tumor suppressor proteins, which are 
involved in the regulation of growth control (27,28). How-
ever, this is a controversial issue, which remains subject 
to debate in HPV-related HNSCC because it depends on 
epidemiological factors as well as technical improvements 
in the detection of HPV (29).
A clearer knowledge of alterations in p16 (INK4a) expres-
sion, as well as their real consequences would contribute 
to the understanding of the pathogenesis of HNSCC. Al-
though p16 (INK4a) may be involved in cell senescence, 
the physiologic role of p16 (INK4a) is still uncertain. In the 
present study, we compared the protein expression and its 
relationship with the two major sites of HNSCC excluding 
the oral cavity, i.e., the larynx and oropharynx. Different 
anatomical sites have not been distinguished in the majority 
of studies involving HNSCC cases. However, the behav-
ior of tumors arising at various sites differs significantly, 
suggesting different intrinsic tumor properties (30). Our 
analysis, in agreement with other HNSCC studies, did not 
show any statistically significant difference between im-
munohistochemical expression of p16 (INK4a) and tumor 
localization, with a similar distribution of positive immunos-
taining being observed at both sites (52.4 and 58.3% in the 
oropharynx and larynx, respectively).
The development and progression of HNSCC have 
been shown to be dependent on various cellular genetic 
Figure 2. Overall survival analysis (A) and disease-free survival (B) of the 75 head and neck squamous cell carcinoma (HNSCC) 
samples studied. HNSCC cases with negative p16 (INK4a) immunolabeling had a shorter survival rate (C) compared to cases with 
positive staining (P < 0.057, log-rank test and Kaplan-Meier method). The overall survival probability (D) was shorter for HNSCC 
patients with positive lymph nodes (N+; P < 0.050, log-rank test and Kaplan-Meier method).
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and epigenetic events, especially alterations of the cell cycle 
machinery at various checkpoints. Among our samples, 
the tumors presenting positive vascular embolization (P 
= 0.018), positive lymphatic permeation (P = 0.002), and 
positive surgical margins (P = 0.050) showed an inverse 
correlation with p16 (INK4a) expression. Hence, p16 
(INK4a)-negative status was associated with more ag-
gressive pathological conditions, probably because this 
protein is critical for the regulation of cell proliferation, and 
the inactivation of this gene is crucial for the tumorigenesis 
process (27). Furthermore, insights into the role of p16 
(INK4a) in cancer have come from the genetic analysis of 
precancerous lesions and various tissue culture models. It 
is now believed that loss of p16 is an early and often critical 
event in tumor progression. Consequently, p16 (INK4a) is 
a major tumor suppressor gene whose frequent loss oc-
curs early in many human cancers (14). Interestingly, p16 
(INK4a) expression was more intense and significantly 
correlated with non-smoker patients (P = 0.050). Kong 
et al. (28) showed that in tobacco-related HNSCC, p16 
(INK4a) is often absent because of homologous deletion 
or promoter hypermethylation.
Regarding survival probability, the 5-year rate for 
HNSCC patients was 48%, which may be explained by 
the fact that in most cases the tumor was diagnosed in 
advanced clinical stages. In agreement with most literature 
data, our results of p16 (INK4a) expression were associated 
with lower overall survival probability (log-rank test, P = 
0.055), suggesting that patients with negative p16 (INK4a) 
protein expression are at a higher risk of death (3,13). To 
further improve survival rates, a clearer understanding of 
the carcinogenic mechanisms involved is important, thereby 
allowing the identification of patients at high risk of devel-
oping tumor recurrences or dying. Similarly, a significant 
association was observed with lower survival probability and 
the presence of lymph node metastasis (log-rank test, P = 
0.0050) and capsular rupture (log-rank test, P = 0.0010). In 
addition, the presence of capsular rupture was associated 
with a higher risk of tumor recurrence (log-rank test, P = 
0.0083). The metastatic dissemination of HNSCC usually 
occurs through the lymphatic system (31). For these tumors, 
metastasis to regional lymph nodes is the strongest predictor 
and the most important prognostic factor, which leads to a 
reduction in the probability of disease control and shorter 
survival of the patients (31,32). There is a critical neces-
sity to understand the molecular mechanisms in HNSCC 
patients. Based on the present outcomes, future studies 
should perhaps focus on the upstream events that lead to 
p16 (INK4a) expression and its mechanism of regulation, 
looking for better therapeutic strategies that can improve 
the clinical course of HNSCC patients because the death 
rate remains extremely high. Gene therapy represents a 
potential opportunity to advance the management of HNSCC 
patients and improve prognosis. 
Our findings suggest that a genetic approach may 
eventually help improve the ability to predict prognosis 
and to prevent the tumor progression of HNSCC patients 
that should enter surveillance programs. Finally, analysis 
of the results obtained in our selected clinical population 
followed for almost a decade showed that it is able to 
predict prognosis on the basis of p16 (INK4a), given that 
its negative expression is important for determining the 
parameters associated with tumor progression and poor 
outcomes in HNSCC.
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